Altos Labs has 2 with an unprecedented $3 billion in funding and a scientific team that reads like a who-who of aging research. The company goal: to reverse age-related disease by programming cellular rejuvenation.
The startup, which operated in stealth mode for over a year, has recruited Nobel laureates, pioneering researchers, and industry veterans to pursue what founder Rick Klausner calls "the biggest bet in biology."
Star-Studded Scientific Team
The roster of scientists joining Altos Labs is remarkable. Shinya Yamanaka, the Nobel laureate who discovered cellular reprogramming, joins as Senior Scientist. Jennifer Doudna, CRISPR pioneer and Nobel laureate, serves on the Advisory Board. Juan Carlos Izpisua Belmonte, the Salk Institute researcher who demonstrated partial reprogramming in mice, leads key research programs. Steve Horvath, creator of the epigenetic clock, and Wolf Reik, epigenetics pioneer from the Babraham Institute, round out the leadership. Scientists are reportedly being offered salaries of $1 million or more plus equity—compensation previously unheard of in academic-style research.
The Cellular Reprogramming Thesis
Altos Labs central bet is that aging can be reversed by resetting cells to a more youthful state without turning them into stem cells. Early research in mice suggests this partial reprogramming can reverse epigenetic marks that accumulate with age, restore youthful gene expression patterns, improve tissue function in aged animals, and extend lifespan in preliminary studies.
Global Research Operations
The company is establishing research institutes across four locations: the San Francisco Bay Area serves as the primary research hub near Stanford and UCSF; San Diego positions the company near the Salk Institute and biotech cluster; Cambridge, UK places researchers adjacent to world-leading epigenetics research; and a Japan facility leverages expertise in iPSC technology.
Funding and Investors
The $3 billion funding round is reportedly backed by Yuri Milner, the Russian-Israeli tech billionaire, and Jeff Bezos through personal investments, along with various institutional investors and family offices. The scale of investment signals that serious money is now flowing into fundamental aging research—a dramatic shift from even five years ago when longevity was considered a fringe field.
Long-Term Vision
"We are not talking about adding a few years to lifespan while people remain frail," says CEO Hal Barron, former GSK R&D chief. "We want to transform how people age—keeping them healthy and functional for decades longer than currently possible." The company is explicitly avoiding near-term commercialization pressure, instead focusing on fundamental research that could yield transformative therapies over a 10-20 year horizon.
